Pierre Fabre announced that they signed a definitive purchase agreement with Igenica Biotherapeutics to acquire several of Igenica assets.
The agreement includes innovative immunotherapies targeting immune checkpoints that may reverse the resistance to existing immuno therapies. The most advanced asset is currently at preclinical stage and is expected to be administered to patients in the coming 2 to 3 years. The agreement also comprises a series of early discovery targets. The financial terms of the agreement are not disclosed.
Head of Pierre Fabre Pharmaceuticals R&D, Laurent Audoly said that this agreement is in line with recent collaborations signed by Pierre Fabre with biotechnology companies and academic laboratories in the fields of oncology and dermatology and confirms their Research & Development dynamic through external partners.
Pierre Fabre Pharmaceutical Division CEO, Frédéric Duchesne said that Pierre Fabre’s know-how in oncology is based on more than 30 years of experience. They have two recognized research and development centers with dedicated teams that work closely together to developing medicines for patients living with cancer. This new deal reinforces their position to participate in the revolution of targeted biotherapies and reinforce their commitment to bring substantial value to patients.
Igenica’s Preclinical Drug Development Senior Director, Edward van der Horst said that they are very pleased that Pierre Fabre will clinically develop Igenica’s most advanced immune oncology asset for patients suffering from cancer.